Abstract: An antibody is disclosed for the detection of phosphorylated c-KIT. A method of diagnosing and monitoring cancers responsive to treatment using an anti-phospho-c-KIT antibody are also disclosed. A diagnostic kit is also provided for the detection and monitoring of cancers responsive to tyrosine phosphorylation inhibitor treatment.
Abstract: Methods of evaluating receptor tyrosine kinase drug efficacy are demonstrated. The methods generally relate to evaluation methods using phospho-RTK over total RTK ratio (pRTK/tRTK). An algorithm is provided that allows the user to combine the pRTK/tRTK ratios from several kinase together with other kinds of measurements to obtain a PDX value that is indicative of drug efficacy.